Cyclooxygenase-2–derived lipoxin A4 increases gastric resistance to aspirin-induced damage

This publication has 25 references indexed in Scilit:

• Unorthodox routes to prostanoid formation: new twists in cyclooxygenase-initiated pathways
  Journal of Clinical Investigation, 2001
• Involvement of the Receptor for Formylated Peptides in the in Vivo Anti-Migratory Actions of Annexin 1 and its Mimetics
  The American Journal of Pathology, 2001
• Effects of specific inhibition of cyclo‐oxygenase‐1 and cyclo‐oxygenase‐2 in the rat stomach with normal mucosa and after acid challenge
  British Journal of Pharmacology, 2001
• Gastrointestinal Toxicity With Celecoxib vs Nonsteroidal Anti-inflammatory Drugs for Osteoarthritis and Rheumatoid Arthritis
  JAMA, 2000
• The discovery of rofecoxib, [MK 966, VIOXX®, 4-(4′-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2 inhibitor
  Bioorganic & Medicinal Chemistry Letters, 1999
• Limited anti‐inflammatory efficacy of cyclo‐oxygenase‐2 inhibition in carrageenan‐airpouch inflammation
  British Journal of Pharmacology, 1999
• Selective cyclo‐oxygenase‐2 inhibitors and their influence on the protective effect of a mild irritant in the rat stomach
  British Journal of Pharmacology, 1998
• Effects of inhibition of prostaglandin endoperoxide synthase‐2 in chronic gastro‐intestinal ulcer models in rats
  British Journal of Pharmacology, 1998
• Mutation of serine‐516 in human prostaglandin G/H synthase‐2 to methionine or aspirin acetylation of this residue stimulates 15‐R‐HETE synthesis
  FEBS Letters, 1994
• Lipoxin generation by permeabilized human platelets
  Biochemistry, 1992